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Abstract  
Background—Pericarditis may be a serious complication of malignancy. Its significance as a 
first symptom of occult cancer and as a prognostic factor for cancer survival is unknown.  
Methods—Using Danish medical databases, we conducted a nationwide cohort study of all 
patients with a first-time diagnosis of pericarditis during 1994–2013. We excluded patients with 
previous cancer and followed the remaining patients for subsequent cancer diagnosis until 
November 30, 2013. We calculated risks and standardized incidence ratios (SIRs) of cancer for
patients with pericarditis compared with the general population. We assessed whether
pericarditis predicts cancer survival by the Kaplan-Meier method and Cox regression, using a
matched comparison cohort of cancer patients without pericarditis.  
Results—Among 13,759 patients with acute pericarditis, 1,550 subsequently were diagnosed 
with cancer during follow-up. The overall cancer SIR was 1.5 (95% confidence interval [CI]:
1.4-1.5), driven predominantly by increased rates of lung, kidney, and bladder cancer, 
lymphoma, leukemia, and unspecified metastatic cancer. The <3-month cancer risk among 
patients with pericarditis was 2.7% and the SIR was 12.4 (95% CI: 11.2-13.7). The 3-<12-month 
SIR of cancer was 1.5 (95% CI: 1.2-1.7), subsequently decreasing to 1.1 (95% CI: 1.0-1.2). 
Three-month survival following cancer diagnosis was 80% and 86% among those with and 
without pericarditis, and the hazard ratio (HR) was 1.5 (95% CI: 1.3-1.8). One-year survival was 
65% and 70%, respectively, corresponding to a 3-<12 month HR of 1.3 (95% CI: 1.1-1.5). 
Conclusions—Pericarditis may be a marker of occult cancer and augurs increased mortality 
following a cancer diagnosis. 
Key Words: pericarditis, pericardial effusion, epidemiology, cancer
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Clinical Perspective
What is new?   
x Patients with newly diagnosed pericarditis had higher risks than age- and sex-matched 
members of the general population of being diagnosed with lung cancer, non-Hodgkin 
lymphoma, and myeloid leukemia during the first 3 months following a pericarditis 
diagnosis.  
x The increased risk for lung cancer, non-Hodgkin lymphoma, and bladder cancer persisted 
beyond 1 year following a pericarditis diagnosis.  
x The increased cancer risk was not restricted to patients with pericardial effusion.
x Pericarditis was a prognostic factor for survival after lung cancer, breast, and bladder 
cancer.   
What are the clinical implications?  
x Patients with pericarditis, particularly when complicated by pericardial effusion, may 
need to be considered for work-up targeted at diagnosing or ruling out cancer.
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Pericarditis, the most common disease of the pericardium, is a relatively benign and self-limiting 
disease1, with an annual incidence rate of approximately 30 per 100,000 persons2. While its
etiology remains elusive in many patients, up to two-thirds of the cases are attributable to 
infection, predominantly with viral pathogens3,4. Other known risk factors are recent 
cardiothoracic surgery, recent myocardial infarction, recent bacterial infection, autoimmune 
disease, and cancer4,5. In unselected cohorts of pericarditis patients, around 5% are attributed to 
cancer etiology4,6,7. However, in patients with pericarditis and pericardial effusion, malignancy is 
more prevalent, ranging between 12% and 23%8-11. 
Cancer-related pericarditis may develop via direct infiltration by malignant cancer cells 
from adjacent structures, pericardial hemorrhage, or hematogenous dissemination of cancer 
cells12. In addition, pericarditis may occur as part of the paraneoplastic syndrome13. Among 
patients with acute pericarditis or pericardial effusions, cancers of the lung and breast and 
hematological malignancies are diagnosed most frequently14-16.  Case reports describe
pericarditis as an early manifestation of lymphoma, gastric cancer, or ovarian cancer17-20.
However, the magnitude of cancer risk in pericarditis patients remains unknown.  
In this Danish cohort study, we examined the risk of subsequent cancer among patients 
with a first-time diagnosis of pericarditis with or without pericardial effusion, compared with the 
general population. As pericarditis may predict an advanced cancer stage, it may also predict
poorer cancer survival. We investigated this hypothesis by comparing survival in matched 
cohorts of cancer patients with and without pericarditis. 
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Methods
Study design and setting
This cohort study was based on the cumulative source population of 7,107,948 persons in 
Denmark, between 1994 and 2013. The Danish healthcare system provides tax-supported 
medical care to all Danish residents, including access to hospitals and outpatient clinics21. In the 
current study, we used data from the Danish National Patient Registry (DNPR)22, in which 
diagnoses are coded according to the International Classification of Diseases, Eighth and Tenth
Revisions (ICD-8 and ICD-10). In the DNPR, the main condition prompting a hospital contact is 
recorded in the ‘primary diagnosis’ field, and other relevant diagnoses are recorded in ‘secondary 
diagnosis’ fields.
 We obtained information on cancer from the Danish Cancer Registry (DCR), which has 
recorded incident primary cancers in Denmark since 194323, classified according to the ICD-10. 
The DCR is virtually complete and its diagnoses are highly valid24.  
Information on mortality was derived from the Danish Civil Registration System (CRS), which 
has monitored changes in vital status and migration on a daily basis for the entire Danish 
population since 1968. 
Patients with acute pericarditis
We identified all patients (hospital inpatients, hospital outpatients, and emergency room 
encounters) with a primary or secondary diagnosis of acute pericarditis (including unspecified 
pericarditis, infectious pericarditis, pericardial effusion, and pericarditis with underlying 
autoimmune disease) using ICD-10 diagnosis codes between January 1, 1994 and November 30, 
2013. We excluded patients diagnosed with pericarditis recorded before 1994.  
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We retrieved information from the DNPR starting in 1977 on comorbidities, including 
tuberculosis, connective tissue disease, and chronic obstructive pulmonary disease as a proxy for 
heavy smoking. We also obtained information on the following diagnoses registered during or 
within 30 days before the hospital contact for pericarditis: cardiothoracic surgery, cardiac 
catheterization, pneumonia/empyema, sepsis, and acute myocardial infarction. We documented 
the number of patients who underwent echocardiography or other relevant imaging of the chest 
in connection with their hospital contact for pericarditis (within 30 days before or after this 
contact). 
Cancer outcomes  
We linked data from the members of the pericarditis cohort to the DCR to identify previous and 
subsequent cancer diagnoses (other than non-melanoma skin cancer) and restricted the 
pericarditis cohort to patients without a previous cancer diagnosis.  
 For the analysis of cancer survival, we selected all patients in the pericarditis cohort who 
subsequently developed cancer, and matched them to up to five cancer patients identified in 
DCR without a pericarditis diagnosis preceding cancer diagnosis, by sex, age (5-year intervals), 
year of pericarditis diagnosis (5-year intervals), and cancer site. For the most frequent cancer 
types (non-Hodgkin lymphoma, lung, breast, bladder, colon, and prostate cancer), we also
matched by cancer stage (Ann Arbor staging for non-Hodgkin lymphoma, and TNM staging for 
other cancers) and repeated the cancer-specific analysis.  
Statistical analysis 
Each patient with pericarditis was followed for cancer occurrence from the date of the first 
hospital contact with a discharge diagnosis of pericarditis until the date of death, emigration, or 
November 30, 2013, whichever came first. The cumulative incidence (or risk) of cancer in 
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patients with pericarditis was computed while treating death (without cancer) as a competing 
risk25. We tested equality of the cumulative incidence functions by sex, age group, pericarditis 
type, type of hospitalization, and type of diagnosis, using Gray´s tests26.  
We used indirect standardized incidence ratios (SIRs) as a measure of relative risk, 
comparing the cancer incidence observed among patients with pericarditis with that expected in 
the general Danish population (the observed number of a specific cancer subtype was compared 
to the expected number of that specific subtype)27.
We computed the expected numbers of cancer cases based on national cancer incidence 
rates by age (+/-1 year), sex, and the calendar year (+/-1 year) of the pericarditis diagnosis. We 
computed 95% confidence intervals (CIs) for the SIRs based on the assumption that the observed 
number of cases followed a Poisson distribution, using the Byar’s approximation28. SIRs were 
computed for all cancers combined and for each cancer type separately. We split the follow-up 
time into three periods: <3 months, 3-<12 months, and 12+ months, determined a priori. The aim
was detecting occurrence of occult cancer related to the acute event (i.e., <3 months), long-term 
cancer risk (i.e., 12+ months), and any potential compensatory deficit indicating detection bias
(i.e., 3-<12 months). We used a single Cox model to obtain the estimates for the various time 
intervals using an interaction between time interval and exposure. We stratified our analyses by
sex, age group (<30, 30-49, 50-69 years), primary vs. secondary diagnosis, type of 
pericarditis, and the covariates. In a post-hoc analysis prompted by large differences in risk by 
pericardial effusion status in our main set of stratified analyses, we computed SIRs for all cancer 
types and by time period for patients with pericardial effusion, and for other pericarditis patients 
without a record of pericardial effusion, to investigate whether any increased risk of cancer 
depended on the presence of pericardial effusion. In the analysis pericarditis as a potential 
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prognostic factor, we constructed Kaplan-Meier survival curves to describe survival of cancer 
patients with and without a pre-cancer pericarditis. We then used Cox proportional-hazards 
regression to compare risks of death between the two cohorts at 3 months, 1 year, and 5 years 
after cancer diagnosis. We calculated hazard ratios (HRs) and associated 95% CIs, adjusting for 
sex, age, calendar year of diagnosis, and cancer type and stage (accounting for the matching by 
forming strata for the baseline hazard for the matched patients). All codes are included in the 
Supplemental Appendix 1.
 The study was approved by the Danish Data Protection Agency, record number 1-16-02-
1-08.  Danish registry data are generally available to researchers, and in accordance with Danish 
law, use of this data does not require informed consent. All statistical analyses were conducted 
using SAS statistical software, v. 9.4 (SAS Institute, Cary, NC, USA). 
Results
Patient characteristics
We identified 13,759 patients with pericarditis during a 20-year period, corresponding to an 
incidence rate of 168 cases per 100,000 persons per year. Median age at pericarditis diagnosis 
was 49 years (interquartile range [IQR]: 34-64 years), and 72% of the patients were male. 
Among the pericarditis patients, 9,758 (71%) had unclassified acute pericarditis, 1,401 (10%)
had acute infectious pericarditis, 2,221 (16%) had pericardial effusion, and the remaining 379 
(3%) had an autoimmune disease.  Prevalent risk factors included recent thoracic surgery (11%), 
pneumonia/empyema (8%), myocardial infarction (6%), heart failure (6%), connective tissue 
disease (4%), implanted pacemaker (4%), tuberculosis (0.5%), and sepsis (1%) (Table 1).
Prevalence of chronic obstructive pulmonary disease and alcohol-related diagnoses was each 4%.  
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Most patients (79%) had pericarditis recorded as their primary discharge diagnosis. The 
remaining patients had the following conditions as the most frequent primary reason for their 
contact: other cardiovascular conditions (myocardial infarction, cardiac insufficiency, and atrial 
fibrillation), pneumonia, and empyema. There were differences in patients´ characteristics 
according to type of hospital contact: patients with emergency room diagnoses tended to be 
younger (median age 34 years) and to have unclassified or infectious pericarditis. These patients 
also had a lower burden of underlying disease than patients with an inpatient or hospital 
outpatient diagnosis of pericarditis. (Supplemental Figure 1)
Overall cancer risk
Overall, there were 1,550 observed new cancer diagnoses among the pericarditis patients vs. 
1,070 expected, during median follow-up of 6.4 years (IQR: 2.5-11.5 years), corresponding to an 
overall SIR of 1.5 (95% CI: 1.4-1.5).  
While all types of pericarditis were associated with an increased risk of subsequent 
cancer, patients with pericardial effusion had the highest incidence rate ratio [SIR = 2.1 (95% CI: 
1.9-2.3)]. For patients with unclassified pericarditis, the SIR was 1.3 (95% CI: 1.2-1.4); for 
patients with acute infectious pericarditis, the SIR was 1.3 (95% CI: 1.0-1.5); and for patients 
with underlying autoimmune disease, the SIR was 1.7 (95% CI: 1.2-2.3). The types of cancer 
underlying this increased cancer risk were cancers of oral cavity, lung, heart, colon, kidney, 
prostate, and bladder, as well as lymphoma, leukemia, and unspecified metastatic cancer (Table 
2).   
Cancer risk during the first year of follow-up
Within the first <3 months following an incident pericarditis diagnosis, 376 cancers were 
diagnosed among the 13,759 pericarditis patients, corresponding to an absolute risk of 2.7%.  
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More than half of the cases were lung cancers (n=210, 56%). Lymphoma accounted for 36 cases, 
leukemia for 16 cases, and unspecified metastatic cancers for 17 cases. The other cancer sites 
had 10 events or fewer each (Table 2). Among cancers diagnosed during the same hospital 
contact as the qualifying pericarditis episode (N = 123), lung cancer accounted for 52% (n = 64), 
non-Hodgkin lymphoma for 9% (n = 11), and 7% (n = 9) had unspecified metastatic cancer.   
The 3-month SIR was 12.4 (95% CI: 11.2-13.7), mainly driven by lung cancer [SIR =
65.0 (95% CI: 56.5-74.4)]. The risk of hematological cancers also was markedly increased 
during first 3 months of follow-up: 30-fold for non-Hodgkin lymphoma and up to 49-fold for 
myeloid leukemia (Table 2). Other sites with excess cancer risks were the heart and thoracic 
cavity, pancreas, ovary, kidney, and bladder. However, the associated estimates were imprecise.
The risk of breast cancer, albeit based on few cases, was increased threefold during this period.   
 During the 3 to <12 months following an incident pericarditis diagnosis, 123 cancers 
were registered, corresponding to a 1-year absolute cancer risk of 3.7% and a SIR of 1.5 (95% 
CI: 1.2-1.7) (Table 2) for any cancer. The observed number of cases was greater than expected 
for lung and bladder cancer, non-Hodgkin lymphoma, and myeloid leukemia.
Cancer risk one year or more following pericarditis
One year or more following pericarditis, 1,051 cancers were diagnosed, compared with 954
expected. This corresponded to a SIR of 1.1 (95% CI: 1.0-1.2). Increased SIRs were observed for 
cancer of the oral cavity, colon, lung, and bladder, and for non-Hodgkin lymphoma. In contrast,
one or more years following a pericarditis diagnosis, no association was found between 
pericarditis and breast, or unspecified metastatic cancers.  
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Subgroup analysis by patient characteristics
Several patient characteristics modified the association between pericarditis and overall cancer 
risk. Both absolute and relative risks were higher in women than men. Absolute cancer risks rose
with increasing age (Table 3). However, relative risks were higher among patients aged under 30 
years than for older patients, compared with the expected risk in the general population (as 
expected given age-dependent increase in cancer risk) (Figure 1). P-values for equality of the 
cumulative incidence functions were <0.0001 (i.e. non-overlapping CIs) in all strata (of sex, age 
groups, different pericarditis types, type of hospitalization and diagnosis). We examined the SIRs 
for the different age groups and follow-up periods, and found that all age groups had elevated 3-
months SIRs, whereas only patients aged 50-69 years had elevated SIRs beyond three months of 
follow-up (Supplemental Table 1).
In particular, pericarditis patients with pericardial effusion had a high 3-month cancer 
risk (9.4%), followed by pericarditis patients with autoimmune disease (4.5%). In contrast, 
patients with infectious pericarditis and unclassified pericarditis had cancer risks of 1.4% (Table 
3).  
While patients with an outpatient or inpatient diagnosis of pericarditis had almost the 
same increase in cancer risk (SIR = 1.5), there was no evidence of an elevated cancer risk 
associated with pericarditis diagnosed only in the emergency room (SIR = 1.0) (not presented in 
a table). Patients with a secondary pericarditis diagnosis had higher absolute cancer risks and a 
higher SIR than did patients with pericarditis as their primary diagnosis (Table 3).
Patients with pericarditis following recent thoracic surgery or recent myocardial 
infarction had a lower SIR for cancer than other pericarditis patients (Figure 1). Patients with 
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chronic obstructive pulmonary disease, alcoholism-related diagnoses, or recent pneumonia had a 
higher SIR for cancer than patients without these diseases.  
Characteristics and cancer risks in patients with and without pericardial effusion
We noted important differences within the groups of pericarditis patients (Supplemental Table 
2). Compared with patients who did not have pericardial effusion, patients who had this 
complication were older (median age, 63 vs. 46 years); had a shorter median follow-up time (4.0 
years vs. 6.9 years); and were more likely to have their diagnosis entered in a secondary 
diagnosis field (34% vs. 19%). The latter difference was consistent with greater prevalence of 
chronic and acute diseases, and recent interventions. Specifically, patients with pericardial 
effusion had a higher prevalence than the remaining pericarditis patients of heart failure (15% vs. 
4%), pacemaker implant (10% vs. 2%), chronic obstructive pulmonary disease (8% vs. 3%), 
pneumonia or empyema (10% vs. 7%), and recent thoracic surgery (42% vs. 5%). Almost all 
(93%) patients with pericardial effusion had an echocardiography-confirmed diagnosis 
(Supplemental Table 2).
Results from the supplemental analyses, estimating SIRs for pericarditis patients with and 
without pericardial effusion, revealed higher cancer risks in patients with than in patients without 
pericardial effusion within the first year after diagnosis. The <3-months SIRs were 26-fold 
increased among patients with and 8-fold among those without pericardial effusion 
(Supplemental Tables 3-4). Cancer-specific SIRs were higher among patients with than among 
those without effusion for lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, and 
unspecified metastatic cancer. While the SIRs of breast and kidney cancers remained elevated 
among patients with pericardial effusion during the first <3 months, we found no association for 
these cancers among other pericarditis patients during the first <3 months of follow-up 
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(Supplemental Tables 3-4). By contrast, the SIRs for prostate and pancreas cancers were elevated 
among patients without pericardial effusion, but not among patients with pericardial effusion 
(Supplemental Tables 3-4). During the 3-<12 months follow-up period, patients with pericardial 
effusion continued to have higher than expected risks of lung cancer and non-Hodgkin 
lymphoma, whereas there was no convincing association for patients without pericardial 
effusion. By contrast, we found a persistently increased SIR for myeloid leukemia only among 
pericarditis patients without pericardial effusion.
 Beyond one year of follow-up, the SIRs of cancer for pericarditis patients with and 
without pericardial effusion were overall in agreement with the main analysis. In particular, the 
risk of lung cancer remained elevated in patients both with and without pericardial effusion. 
Patients without pericardial effusion had an elevated SIR of cancers of the oral cavity, whereas 
no cases of this cancer type were observed among those with pericardial effusion. Only patients 
without pericardial effusion remained at an increased risk of colon cancer (Supplemental Tables 
3-4).
Pericarditis as prognostic factor for cancer patients
The survival analyses included 1,550 patients with pericarditis preceding their cancer diagnosis, 
and a matched cohort of 7,664 cancer patients without antecedent pericarditis. Reflecting 
successful matching, median age was 67 years (IQR: 59-75 years) and 67% patients were male in 
both cohorts. Among the pericarditis patients, 40% had localized cancer, 36% had metastatic 
cancer and 24% had unknown or missing cancer stage. The corresponding proportions for
patients without pericarditis were 42%, 37%, and 22%.
 Regardless of presence of pericarditis before a cancer diagnosis, the cancer patients had 
poor outcomes (Figure 2). Three-month survival after any cancer was 80% for patients with and 
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86% for patients without pericarditis, corresponding to an adjusted HR of 1.5 (95% CI: 1.3-1.8) 
for cancer overall. For specific malignancies, the adjusted three-month HR was 1.7 (95% CI: 1.4-
2.0) for lung cancer, 2.0 (95% CI: 0.4-10.3) for breast cancer, and 0.8 (95% CI: 0.3-2.5) for non-
Hodgkin lymphoma (Table 4). Survival at one year was 65% for patients with and 70% patients 
without pericarditis, and the 3-12 month HR was 1.3 (95% CI: 1.1-1.5). 
Over time, pericarditis remained a prognostic factor for impaired cancer survival; after
five years of follow-up, survival was 44% among cancer patients with previous pericarditis and 
48% among patients without previous pericarditis (Figure 2). HRs 1-<5 years after a cancer 
diagnosis preceded by pericarditis indicated persistent increased mortality for bladder cancer 
(HR = 2.4 [95% CI: 1.3-4.2]) and breast cancer (HR = 2.2 [95% CI: 1.1-4.8]) (Table 4).
Discussion
In this population-based nationwide cohort study, pericarditis was a marker for occult cancer. In 
particular, we observed a higher than expected rate of lung cancer, non-Hodgkin lymphoma, and 
myeloid leukemia during the first 3 months after an incident pericarditis diagnosis. While the 
excess risk decreased for several cancers after the first 3 months for, it nevertheless persisted for 
lung cancer, non-Hodgkin lymphoma, and bladder cancer diagnoses up to several years after a 
pericarditis diagnosis. Importantly, we observed an increased cancer risk both in patients with 
and without pericardial effusion. No previous study has compared the prognostic impact of 
pericarditis preceding cancer diagnosis.  We found that pericarditis was a prognostic factor for 
both short-term cancer survival after lung cancer, and long-term cancer survival after bladder and 
breast cancer.    
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Primary tumors of the heart are rare, and the majority of cancer-related pericarditis cases 
are caused by metastatic tumors of remote origin29. The most common cancers with a known 
potential to spread to the pericardium include lung and breast cancer, lymphoma, and leukemia12.
Other cancers leading to pericarditis through hematogenous spread include thymic, esophageal, 
bladder, kidney, and ovarian cancers7,29. Moreover, pericarditis may occur as a part of the 
paraneoplastic syndrome13. In our unselected cohort of previously “cancer free” patients, we 
corroborated some associations that earlier were described only as case reports 17-20 or in small 
cohort studies (maximum of 453 patients) without comparison cohorts4,6,7.   
Most previous studies of pericarditis have sought to characterize its underlying causes
and to examine prognostic factors for mortality 4,15,30. The prognosis among patients with 
pericarditis is usually good,31 but some characteristics are associated with a less favorable 
course. Co-infections (pneumonia and sepsis) and heart failure in patients with pericarditis 
increase in-hospital mortality15, while fever > 38ƕC, large effusions/tamponade, and NSAID 
treatment failure are associated with poor 6-12 month survival4. Bacterial pericarditis, especially 
purulent pericarditis, is fatal if untreated, and mortality is high even in patients receiving proper 
treatment32. Among patients with known cancer, purulent pericarditis and pericardial effusion 
have serious implications for prognosis5,33,34.  
 All Danish residents have tax-supported universal access to medical care, including 
hospital admission and treatment, which minimizes the risk of selection bias. Data in the DNPR 
are recorded by treating clinicians and registered mainly for administrative use. As it is 
mandatory to report incident cancers to the DCR, we had complete cancer ascertainment (used 
both for exclusion of previous cancers and for cancer diagnosed during follow-up). The registry 
diagnoses included in our study generally are of high quality22,23, and the positive predictive 
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value of hospital-based pericarditis is 92% (95% CI: 85-96%) overall, and 97% (95% CI: 91-
99%) for inpatient diagnoses35. Because pericarditis is a serious disease, it is likely to lead to 
hospitalization, with diagnoses made mainly at highly specialized centers. Thus, validity and 
completeness of our pericarditis definition are likely high. 
 However, our findings reflected outcome of pericarditis in patients with symptoms 
sufficiently severe to necessitate hospital referral by general practitioners or the prehospital 
emergency service and may differ from the outcome in patients with trivial symptoms of 
pericarditis.
Data on the incidence of pericarditis are sparse. One study reported an annual incidence 
of 30 per 100,000 persons, based on 274 patients diagnosed with pericarditis at two general 
hospitals (covering an urban area of 220.000 inhabitants)2. In comparison, we included a 
nationwide cohort capturing persons from the entire population of Denmark (approx. 7 million 
people alive between 1994 and 2013) diagnosed with pericarditis at both general hospitals and 
university hospitals. The difference may thus be explained by our population-based setting.
A number of limitations must also be considered. There were some limitations in the clinical 
details available at patient level in our register-based data. We had no information on the clinical 
presentation, and therefore could not examine potential differences in cancer risk according to 
the clinical presentation.
 Though the overall PPV for pericarditis diagnosis is high, there may have been 
misclassification between the subtypes of pericarditis, potentially diluting differences in the 
associations of different subtypes with cancer.   
 We adjusted for age and sex by indirect standardization; whereas we did not adjust for 
other factors. While life style factors are not strong risk factors for pericarditis, they may have 
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modified the cancer risk. Unfortunately, we lacked data to sufficiently examine potential effect 
modification by smoking and alcohol use.   
 Patients with pericarditis as a secondary diagnosis of had a higher risk of cancer than 
patients with pericarditis as the primary reason for their hospital contact. Pericarditis in a 
secondary position is indicative of additional or more severe morbidities at the time of the 
pericarditis diagnosis, which could explain the findings. Potentially, symptoms suggestive of 
cancer could have led to more thorough examination of these patients.  
A few clinical factors may signal neoplastic origin of pericarditis, e.g. unremitting course 
or recurrent episodes, pericardial effusion, or inefficient recovery after NSAIDs treatment14. We 
confirmed that pericardial effusion is associated with high cancer risk; in fact, almost every tenth 
patient with pericardial effusion had a cancer diagnosis within the first 3 months after the 
pericarditis diagnosis.  
 We found especially high risks of lung cancer and non-Hodgkin lymphoma in patients 
with pericardial effusion, but also a higher short-term risk of lung cancer, breast cancer, non-
Hodgkin lymphoma, and unspecific metastatic cancer. Patients without pericardial effusion had 
higher short-term risks of myeloid leukemia and prostate cancer, and long-term risks of colon 
cancer and cancer of the oral cavity.
 Patients with pericardial effusion were older, and had higher prevalence of heart failure, 
pacemaker implants, chronic obstructive pulmonary disease, and recent thoracic surgery than 
patients without pericardial effusion.  
The overall stratified analyses showed that presence of heart failure, chronic obstructive 
pulmonary disease, alcohol-related diagnoses, tuberculosis, and recent pneumonia or empyema, 
was associated with elevated cancer SIRs among pericarditis patients. While these conditions are 
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known to be associated with increased cancer risk 36-38, they are not considered important 
confounders in the relation between pericarditis and cancer. However, they could potentially be 
modifiers of the cancer risk among pericarditis patients. Accordingly, patients with these 
conditions may have an increased risk of cancer and should thus be classified as high-risk 
patients. By contrast, patients with recent thoracic surgery or recent myocardial infarction had a 
lower SIR than patients without this history. This finding accord with a lower a priori cancer risk 
among patients with underlying diseases not strongly related to cancer. However, the lower SIR 
for patients who underwent thoracic surgery may also indicate that patients with obvious signs of 
cancer were deemed unsuitable for surgery.  
 In agreement with the previous guidelines for diagnostic work-up in patients with 
pericarditis, the work-up conducted in patients in our cohort may have been targeted mainly at 
excluding myocardial infarction (i.e., ECG, echocardiography, examination of biomarkers for 
acute cardiac ischemia, chest x-ray). However, the updated guidelines recommend additional 
assessment of markers of inflammation (i.e., CRP and/or erythrocyte sedimentation rate [ESR]), 
white blood cell count with differential count, renal function, liver tests, and tests indicating 
myocardial lesion (creatine kinase and troponin) in all cases of suspected pericarditis1. In 
addition, further testing (e.g. CT scan) is indicated in high-risk patients according to clinical 
indicators (fever >38ƕC, subacute course, large pericardial effusion, cardiac tamponade, and/or 
failure of aspirin or NSAIDs)1.
The clinical value of the different diagnostic tests was summarized in a review, showing 
that malignancy as etiology shares several features with other causes8. Clinical examination with 
auscultation, ECG, echocardiography, and markers of inflammation does not discriminate 
between etiologies, whereas more specific tumor makers and CT or CMR could lead to 
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diagnosis8. In a study examining 55 patients with effusion, CT revealed pathological findings in 
all patients with malignancy, whereas clinical and biochemical data were not able to differentiate 
between malignant or non-malignant causes39. The final diagnostic of neoplastic pericarditis 
requires isolation of neoplastic cells from pericardial fluid by pericardiocentesis and histological 
examination of pericardial biopsies5. 
The frequent use of x-ray or other imaging examinations in our cohort could have 
revealed lung cancer or lymphoma, or led to a more thorough investigation that identified
cancers, which may or may not have been related to pericarditis. Accordingly, our results for the 
initial 3-month follow-up period are likely influenced by heightened diagnostic effort to some 
degree. We observed an increased risk of most cancers during that period, but no clear
compensatory drop in incidence ratios in the later follow-up period. Without access to patients’ 
medical records, it is difficult to differentiate patients whose pericarditis was the first 
manifestation of advanced cancer, from those coincidentally occurring with cancer.  In contrast, 
cancers diagnosed more than one year after a pericarditis diagnosis are unlikely to be subject to 
detection bias, although some may have been present at the time of pericarditis diagnosis. 
 Clinically it is important to know whether patients presenting with first-time pericarditis 
should be investigated more thoroughly to rule-out specific cancers. An x-ray examination
potentially could lead to detection of lung cancer, metastatic cancer, or lymphoma. We speculate 
that if the standard work-up in our cohort of patients had included such tests as a complete blood 
count, liver enzyme level, and CT scan, then additional cancers might have been detected earlier.
Patients, both with and without effusion had elevated relative risks of several cancers but the 
absolute risks were low. Accordingly, the ‘number needed to examine’ to detect additional 
cancers would be high.  Thus, economic and patient-related costs, including exposure to 
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radiation and anxiety associated with the diagnostic work-up may outweigh the clinical utility of 
an extended screening such as whole body scans. Nevertheless, our results may raise awareness 
for lung cancer and non-Hodgkin lymphoma in patients presenting with pericardial effusion. 
In conclusion, pericarditis may be a marker of occult lung and breast cancer, as well as 
hematological and unspecified metastatic cancers. The increased diagnosis rate of cancers of the 
heart and thoracic cavity, pancreas, kidney, and bladder, which may represent metastatic spread
of such cancers to the pericardium. While cancer risk was increased in patients both with and 
without pericardial effusion, pericardial effusion was associated with particular high cancer 
incidence, specifically lung cancer, lymphoma, and unspecified metastatic cancer.  Even though 
pericarditis is associated with a worse survival among patients with certain cancers, it is unclear 
whether an earlier detection of cancer improves survival.  
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Table 1. Characteristics of 13,759 patients with acute pericarditis, Denmark, 1994-2013. 
* During the same hospital contact or within 30 days before a hospital contact for pericarditis.
† Since 1977  
‡30 days prior to or after diagnosis (only available for patients diagnosed after 2002).
N (%)
Men 9,865 (72)
Age groups, years
<30  
30-49 
50-69  
70+
2,663 (19)
4,386 (32)
4,544 (33)
2,166 (16)
Type of diagnosis
Primary
Secondary
10,869 (79) 
2,890 (21)
Type of hospital contact
Inpatient 
Outpatient  
Emergency room     
11,247 (82) 
1,037 (7)
1,475 (11)
Recent procedure*
Thoracic surgery
Cardiac catheterization      
Recent diagnosis* 
Myocardial infarction
Pneumonia or empyema 
Sepsis
Previous diagnosis†
Tuberculosis 
Connective tissue disease 
Chronic obstructive pulmonary disease 
Alcoholism-related diagnosis 
Heart failure
Pacemaker
Recent imaging‡
     Echocardiography 
Chest x-ray, CT or MR
1,499 (11)  
109 (1)
764 (6)
1,046 (8)
152 (1) 
71 (0.5) 
557 (4)
537 (4)
538 (4)
814 (6)
494 (4) 
6,537 (72) 
7,628 (84)
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Table 2. Standardized incidence ratios for cancer in 13,759 patients with acute pericarditis.
Observed cancers, standardized incidence ratios (95% confidence interval), and 3-month risk (%)
Cancer site 0 to <3 months 3 to <12 months 12+ months Overall
Any 376 12.4 (11.2–13.7) 2.7 123 1.5 (1.2–1.7) 1,051 1.1 (1.0–1.2) 1,550 1.5 (1.4–1.5)
Oral cavity 0 – 0.0 1 2.0 (0.1–11.3) 12 2.3 (1.2–4.0) 13 2.2 (1.2–3.7)
Esophagus 1 2.7 (0.1 –15.0) 0.0 3 2.9 (0.6–8.4) 10 0.8 (0.4–1.6) 14 1.1 (0.6–1.8)
Stomach 1 2.2 (0.1–12.0) 0.0 0 – 13 0.9 (0.5–1.6) 14 0.9 (0.5–1.5)
Colon 9 4.5 (2.1–8.5) 0.1 6 1.1 (0.4–2.3) 78 1.3 (1.0–1.6) 93 1.4 (1.1–1.7)
Rectum 1 0.9 (0.0–4.9) 0.0 2 0.6 (0.1–2.3) 37 1.1 (0.8–1.5) 40 1.0 (0.7–1.4)
Pancreas 4 6.1 (1.7–15.7) 0.0 4 2.2 (0.6–5.6) 19 0.9 (0.6–1.5) 27 1.2 (0.8–1.7)
Lung, bronchi, or trachea 210 65.0 (56.5–74.4) 1.5 19 2.1 (1.3–3.3) 132 1.4 (1.2–1.6) 361 3.3 (3.0–3.7)
Heart and thoracic cavity 4 337 (92–862) 0.0 1 31.5 (0.8–175) 2 6.4 (0.8–23.1) 7 19.7(7.9–40.5)
Breast 6 2.8 (1.0–6.2) 0.0 6 1.0 (0.4–2.2) 48 0.9 (0.6–1.1) 60 0.9 (0.7–1.2)
Ovary 5 17.2 (5.6–40.0) 0.0 1 1.2 (0.0–6.9) 8 1.1 (0.5–2.2) 14 1.7 (0.9–2.9)
Prostate 10 2.9 (1.4–5.3) 0.1 11 1.1 (0.6–2.0) 141 1.1 (0.9–1.3) 162 1.2 (1.0–1.4)
Kidney 6 12.1 (4.5–26.4) 0.0 4 2.9 (0.8–7.4) 20 1.3 (0.8–2.0) 30 1.7 (1.2–2.4)
Bladder 3 1.9 (0.4–5.5) 0.0 11 2.5 (1.2–4.4) 73 1.5 (1.2–1.9) 87 1.6 (1.3–2.0)
Brain 4 6.0 (1.6–15.3) 0.0 5 2.6 (0.9–6.2) 16 0.8 (0.5–1.3) 25 1.1 (0.7–1.6)
Hodgkin malignant lymphoma 6 64.7 (23.8–141) 0.0 0 – 2 0.8 (0.1–2.9) 8 2.8 (1.2–5.5)
Non-Hodgkin malignant lymphoma 30 29.9 (20.2–42.7) 0.2 8 2.9 (1.2–5.6) 44 1.4 (1.0–1.9) 82 2.3 (1.9–2.9)
Lymphoid leukemia 4 11.5 (3.1–29.3) 0.0 0 – 10 0.9 (0.5–1.7) 14 1.2 (0.6–2.0)
Myeloid leukemia 11 48.9 (24.4–87.5) 0.1 5 8.0 (2.6–18.7) 7 1.1 (0.4–2.2) 23 3.1 (2.0–4.6)
Unspecified metastatic cancer 17 30.5 (17.8–48.9) 0.1 1 0.6 (0.0–3.6) 12 0.8 (0.4–1.3) 30 1.7 (1.1–2.4)
Malignant melanoma 2 2.2 (0.3–7.9) 0.0 1 0.4 (0.0–2.1) 26 0.9 (0.6–1.3) 29 0.9 (0.6–1.2)
Basal cell carcinoma 4 0.7 (0.2–1.7) 0.0 15 0.9 (0.5–1.5) 205 1.0 (0.9–1.2) 224 1.0 (0.9–1.1)
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Table 3. Three-month and one-year risks of any new cancer diagnosis in 13,759 patients with 
acute pericarditis.
Risk in % (95% CI)
Characteristics 3 months 1 year
Overall
Women
Men
2.7 (2.5-3.0)
4.8 (4.2-5.5) 
1.9 (1.7-2.2)
3.7 (3.4-4.0)
6.2 (5.4-6.9) 
2.7 (2.4-3.0)
Age groups, yr
     <30 
     30-49 
     50-69 
70+
0.6 (0.4-1.0) 
1.1 (0.8-1.5) 
4.6 (4.0-5.2) 
4.8 (4.0-5.8)
0.7 (0.4-1.1) 
1.4 (1.1-1.8) 
5.9 (5.2-6.6) 
7.3 (6.3-8.5)
Type of pericarditis
Unclassified
Pericardial effusion
Infectious pericarditis
Autoimmune disease
1.4 (1.1-1.6) 
9.4 (8.3-10.7) 
1.4 (0.9-2.1) 
4.5 (2.7-6.9)
2.2 (1.9-2.5) 
11.1 (9.8-12.4) 
1.9 (1.3-2.7) 
5.0 (3.1-7.6)
Type of hospital contact
     Inpatient 
     Outpatient 
Emergency room
3.1 (2.8-3.4) 
2.7 (1.9-3.9) 
0.3 (0.1-0.8)
4.0 (3.7-4.4) 
4.1 (3.0-5.5) 
0.7 (0.4-1.2)
Type of diagnosis
Primary 
Secondary
2.5 (2.2-2.8) 
3.7 (3.0-4.4)
3.3 (3.0-3.7) 
4.9 (4.1-5.7)
P-values for equality of the cumulative incidence functions were <0.0001 in all strata (within gender, 
within age groups, within different pericarditis types, within type of hospitalization and diagnosis).
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Table 4. Adjusted hazard ratios (HRs) of mortality among 1,550 patients with cancer and prior 
pericarditis and a matched cohort of 7,664 patients with cancer and no prior pericarditis. 
*Patients were matched by age, sex, and type cancer.
† In the overall analyses (any cancer), the HRs were adjusted for cancer stage. For the specific cancer types, we
matched by cancer stage.
‡ Total number of deaths five years after cancer diagnosis.
Cancers Pericarditis* No pericarditis* Adjusted HR and 95% confidence interval†
N Deaths, n‡ N Deaths, n‡ 0-<3 months 3-<12 months 1-<5 years
Any cancer 1,550 824 7,664 3757 1.5 (1.3-1.8) 1.3 (1.1-1.5) 1.2 (1.0-1.3)
Lung 326 296 1,630 1435 1.7 (1.4-2.0) 1.1 (0.8-1.4) 1.0 (0.7-1.6)
Breast 51 17 255 48 2.0 (0.4-10.3) 1.2 (0.3-4.3) 2.2 (1.1-4.8)
Non-Hodgkin lymphoma 39 12 183 69 0.8 (0.3-2.5) 0.8 (0.3-2.6) 0.7 (0.2-2.0)
Bladder 45 30 225 110 1.6 (0.5-4.9) 1.4 (0.6-3.7) 2.4 (1.3-4.2)
Colon 78 40 390 213 0.8 (0.4-1.6) 0.8 (0.4-1.7) 1.1 (0.6-2.0)
Prostate 90 26 450 137 0.2 (0.0-1.7) 3.3 (1.4-7.4) 0.7 (0.4-1.3)
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Figure Legends
Figure 1. Standardized incidence ratios for cancer in 13,759 patients with acute pericarditis, 
stratified according to patient characteristics.
Figure 2. Survival among cancer patients with and without a prior pericarditis diagnosis.


